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Abstract Hyponatremia is the most common electrolyte
abnormality encountered in children. In the past decade,
new advances have been made in understanding the
pathogenesis of hyponatremic encephalopathy and in its
prevention and treatment. Recent data have determined
that hyponatremia is a more serious condition than
previously believed. It is a major comorbidity factor for
a variety of illnesses, and subtle neurological findings
are common. It has now become apparent that the
majority of hospital-acquired hyponatremia in children
is iatrogenic and due in large part to the administration
of hypotonic fluids to patients with elevated arginine
vasopressin levels. Recent prospective studies have
demonstrated that administration of 0.9% sodium chlo-
ride in maintenance fluids can prevent the development
of hyponatremia. Risk factors, such as hypoxia and
central nervous system (CNS) involvement, have been
identified for the development of hyponatremic enceph-
alopathy, which can lead to neurologic injury at mildly
hyponatremic values. It has also become apparent that
both children and adult patients are dying from symp-
tomatic hyponatremia due to inadequate therapy. We
have proposed the use of intermittent intravenous bolus
therapy with 3% sodium chloride, 2 cc/kg with a
maximum of 100 cc, to rapidly reverse CNS symptoms
and at the same time avoid the possibility of over-
correction of hyponatremia. In this review, we discuss
how to recognize patients at risk for inadvertent over-
correction of hyponatremia and what measures should
taken to prevent this, including the judicious use of
1-desamino-8d-arginine vasopressin (dDAVP).
Keywords Hyponatremia.Encephalopathy.Cerebral
edema.Pulmonaryedema.Fluidtherapy.Saline.
Sodiumchloride.Myelinolysis.Argininevasopressin
Introduction
Hyponatremia is one of the most common electrolyte
abnormalities encountered in children, with mild hypo-
natremia, serum sodium (SNa) <135 mEq/L, occurring in
∼25% of hospitalized children and moderate hyponatre-
mia, SNa <130 mEq/L, in ∼1% (Table 1). Recent data in
both children and adults have demonstrated that hypona-
tremia is a far more serious condition than previously
believed. The most serious complication of hyponatremia
is hyponatremic encephalopathy. Hyponatremic encepha-
lopathy is a topic that has been mired in controversy. The
main disputes have centered on (1) the most appropriate
fluid management strategies to prevent hyponatremic
encephalopathy, (2) the optimal therapy for symptomatic
hyponatremia, and (3) the risks of developing cerebral
demyelination from the correction of hyponatremia. In this
review, we discuss new aspects in the pathogenesis of
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Why does hyponatremia develop?
Under normal circumstances, the human body can
maintain plasma sodium levels within the normal range
(135–145 mEq/L), even with wide fluctuations in fluid
intake. The body’s primary defense against developing
hyponatremia is the kidney’s ability to generate a dilute
urine and excrete free water. Rarely is excess ingestion
of free water alone the cause of hyponatremia, as an
adult with normal renal function can typically excrete
>15 L of free water per day [1]. It is also rare to develop
hyponatremia from excess urinary sodium loss in the
absence of free-water ingestion. In order for hyponatremia
to develop, there must typically be a relative excess of free
water in conjunction with an underlying condition that
impairs the kidney’s ability to excrete free water (see
Table 2). Excretion of free water will be impaired when
there is either (1) a marked reduction in glomerular
filtration rate, (2) renal hypoperfusion, or (3) arginine
vasopressin (AVP) excess. Most cases of hyponatremia are
the result of increased AVP production.
Renal water handling is primarily under the control of AVP,
which is produced in the hypothalamus and released from the
posterior pituitary. The action of AVP is mediated via the
vasopressin V2 receptor. AVP binding of V2 receptors results
in the insertion of aquaporin 2 (AQP2) water channels on the
apical surface of the principal cells of the cortical collecting
duct,whichmarkedlyincreaseswaterpermeabilityandimpairs
water excretion [2]. There are osmotic, hemodynamic, and
nonhemodynamic stimuli for AVP release. The body will
attempt to preserve extracellular volume at the expense of
SNa. Therefore, a hemodynamic stimulus for AVP production
will override any inhibitory hypo-osmolar effect of hypona-
tremia [3]. There are numerous hemodynamic and non-
hemodynamic stimuli for AVP production (Table 1)t h a to c c u r
in hospitalized patients and that can put virtually any
hospitalized patient at risk for hyponatremia. In order for
hyponatremia to develop in the presence of AVP excess, there
must be an additional source of free-water intake, either
intravenous or oral. Even isotonic fluid administration could in
theoryresultinhyponatremiainthepresenceofAVPexcess,as
the kidney can generate free water by excreting a hypertonic
urine, i.e. a urine sodium plus potassium concentration greater
than that of the plasma [4].
& Hyponatremia typically results from the combination
of AVP excess plus free water intake.
Is asymptomatic hyponatremia a benign condition?
Increased attention has been focused on the possible
deleterious consequences of asymptomatic hyponatremia.
Most of this data comes from adult studies, but pediatric
data are starting to appear. Recent data have revealed that
hyponatremia is an independent predictor of mortality in
Table 1 Incidence of hyponatremia in hospitalized children
Author Inclusion criteria serum sodium (mEq/L) Incidence (%)
Hasegawa et al. 2009 [121] <135 on admission 17
Don et al. 2008 [122] <135 on admission with community-acquired pneumonia 45
Hoorn et al. et al. 2004 [123] <135 in emergency department patients with serum sodium checked 22
Armon et al. 2008 [124] Hospitalized patients on intravenous fluids
<135 24
<130 5
Wattad et al. 1992 [125] <130 in hospitalized patients 1.4
Table 2 Disorders in impaired renal water excretion
1. Effective circulating volume depletion
a) Gastrointestinal losses: vomiting, diarrhea
b) Skin losses: cystic fibrosis
c) Renal losses: salt-wasting nephropathy, diuretics, cerebral salt
wasting, hypoaldosteronism
d) Edematous states: heart failure, cirrhosis, nephrosis,
hypoalbuminemia
e) Decreased peripheral vascular resistance: sepsis, hypothyroidism
2. Thiazide diuretics
3. Renal failure
a) Acute
b) Chronic
4. Non-hypovolemic states of antidiuretic hormone (ADH) excess
a) Syndrome of inappropriate secretion of antidiuretic hormone
(SIADH)
b) Nausea, emesis, pain, stress
c) Post-operative state
d) Cortisol deficiency
5. Nephrogenic syndrome of inappropriate antidiuresis (NSIAD)
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patients with pneumonia, congestive heart failure, and end-
stage liver disease [5–7]. It has recently been demonstrated
that mild chronic hyponatremia (mean SNa 128 mEq/L) in
adults can result in subtle neurological impairment affecting
both gait and attention, similar to that of moderate alcohol
intake [8]. This appears to explain why hyponatremia has
come to be associated with falls and bone fractures in the
elderly [8–10].
There are data to suggest that hyponatremia has
deleterious consequences in the preterm neonate, though
data are lacking in older children. Preterm neonates with
hyponatremia show impaired growth and development
compared with those who have been salt supplemented
[11, 12] and have increased sodium intake as adolescents
[13]. Hyponatremia is also a significant risk factor for
sensorineural hearing loss [14], cerebral palsy [15], and
intracranial hemorrhage [16]. Hyponatremia has been
shown to be a risk factor for increased mortality in neonates
who suffered perinatal birth asphyxia [17].
& Asymptomatic hyponatremia in adults is associated
with attention and gait abnormalities, falls and frac-
tures, and increased mortality in patients with pneumo-
nia, heart failure and liver disease.
& Asymptomatic hyponatremia in preterm neonates is
associated with poor growth and development, senso-
rineural hearing loss, and increased sodium intake in
later life.
What are the clinical features of hyponatremic
encephalopathy?
Hyponatremic encephalopathy is a medical emergency that
can be lethal. The pathogenesis and epidemiology of
hyponatremic encephalopathy have been reviewed in detail
by us elsewhere [18–20]. The primary symptoms of
hyponatremia are those of cerebral edema (see Table 3).
Hypoosmolality results in intracellular or cytotoxic cerebral
edema caused by the influx of water into the intracellular
space down a concentration gradient, resulting in paren-
chymal brain swelling. Cerebral edema results in increased
intracranial pressure that can lead to brain ischemia,
herniation, and death. The brain’s primary mechanism in
adapting to hyponatremia is the intracellular extrusion of
electrolytes and organic osmolytes. Some of these organic
osmolytes are excitatory amino acids, such as glutamate
and aspartate, that can produce seizures in the absence of
detectable cerebral edema [21].
Hyponatremic encephalopathy can be difficult to recog-
nize, as the presenting symptoms are variable and can be
nonspecific (see Table 3). The only universal presenting
features of hyponatremic encephalopathy are headache,
nausea, vomiting, and lethargy. These symptoms can easily
be overlooked, as they occur in a variety of conditions. There
must be a high index of suspicion for diagnosing hypona-
tremic encephalopathy, as the progression from mild to
advanced symptoms can be abrupt and does not follow a
consistent progression. A cranial computed tomography (CT)
scan cannot consistently be used to rule out hyponatremic
encephalopathy, as it is not sensitive enough to detect mild
cerebral edema that could be detected by diffusion-weighted
magnetic resonance imaging (MRI) [22, 23].
A common yet underrecognized feature of hyponatremic
encephalopathy is noncardiogenic pulmonary edema, also
referredtoasAyus-Arieff syndrome[24, 25]. Cerebral edema
leads to increased intracranial pressure, which can result in
pulmonary edema via two mechanisms: (1) centrally
mediated increase in pulmonary vascular permeability to
proteins, leading to increased alveolar and interstitial fluid
[26], and (2) increased sympathetic neuronal activity with
catecholamine release, resulting in pulmonary vasoconstric-
tion with increased capillary hydrostatic pressure and
capillary wall injury (Fig. 1)[ 27, 28]. This has primarily
been reported in patients with postoperative hyponatremic
encephalopathy and exercise-associated hyponatremia [29,
30]. It is important to recognize this syndrome, as it is
rapidly reversible with hypertonic saline and is almost
universally fatal if left untreated.
& The most consistent clinical features of hyponatremic
encephalopathy are headache, nausea, and vomiting.
1. Early
a. Headache
b. Nausea and vomiting
c. Lethargy
d. Weakness
e. Confusion
f. Altered consciousness
g. Agitation
h. Gait disturbances
2. Advanced
a. Seizures
b. Coma
c. Apnea
d. Pulmonary edema
e. Decorticate posturing
f. Dilated pupils
g. Anisocoria
h. Papilledema
i. Cardiac arrhythmias
j. Myocardial ischemia
k. Central diabetes insipidus
Table 3 Clinical symptoms of
hyponatremic encephalopathy
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nized feature of hyponatremic encephalopathy.
& Hyponatremic encephalopathy can occur in the absence
of CT evidence of cerebral edema.
What are the risks factors for developing hyponatremic
encephalopathy?
Here we describe the major risk factors for hyponatremic
encephalopathy development (Table 4).
Children
It is important to realize that children are at significantly
higher risk than are adults for developing hyponatremic
encephalopathy. The average SNa in children with hypo-
natremic encephalopathy is 120 mEq/L [31, 32], whereas
that in adults is 111 mEq/L [9, 31–33]. More than 50% of
children with an SNa <125 mEq/L will develop hypona-
tremic encephalopathy [20]. The reason for this is that
children have a relatively larger brain to intracranial volume
ratio compared with adults [34, 35]. A child’s brain reaches
adult size by 6 years of age, whereas the skull does not
reach adult size until 16 years of age [36, 37]. As a result,
children have less room available in their rigid skulls for
brain expansion and are likely to develop brain herniation
from hyponatremia at higher SNa concentrations than
adults. The fontanelles in infants appear to offer little
protection, as the incidence of hyponatremic encephalopa-
thy in infants is quite high [38].
Factorsthatimpairbrain-cell-volumeregulationanddecrease
cerebral perfusion: female sex steroids, elevated AVP,
and hypoxia
There are various factors that can impair the normal brain
regulatory volume decrease and place patients at increased
risk for the development of hyponatremic encephalopathy,
independentofthedegreeofhyponatremiaortherateoffallin
SNa. The primary factors are female sex steroids, elevated
AVP levels, and hypoxia. Women in their reproductive years
are at high risk for developing hyponatremic encephalopathy
[33]. The reason for this appears to be that estrogens impair
brain-cell-volume regulation by reducing the sodium/
potassium/adenosine triphosphatase (Na+/K+/ATPase)
pump activity, thereby inhibiting sodium extrusion from
brain astrocytes. Androgens, on the other hand, appear to
enhance Na+/K+/ATPase pump activity and confer a
protective role in men [18]. Another reason that women
are more susceptible to hyponatremic encephalopathy is
that the vasoconstrictive effects of AVP are more pro-
nounced in the female brain than in that of the male brain.
AVP excess leads to cerebral vasoconstriction with
Hyponatremia 
Cytotoxic cerebral edema 
Increased intracranial pressure 
Centrally mediated increased 
vascular permeability 
Catecholamine release 
Pulmonary vasoconstriction 
Elevated capillary 
hydrostatic pressure 
Capillary wall injury 
Non-cardiogenic pulmonary edema 
Fig. 1 Mechanism of noncardiogenic pulmonary edema in hypona-
tremic encephalopathy
Table 4 Risk factors for developing hyponatremic encephalopathy
1) Impaired brain cell volume regulation and decreased cerebral
perfusion
a) Elevated AVP levels
b) Female sex steroids
c) Hypoxia
2) Decreased cranial capacity
a) Children <16 years
b) Space-occupying brain lesion
i) Tumor
ii) Hematoma/hemorrhage
c) Hydrocephalus
i) Chiari malformation
ii) Dandy Walker
3) Central nervous system disorders (cytotoxic and vasogenic cerebral
edema)
a) Infections
i) Meningitis/encephalitis
b) Encephalopathy
i) Metabolic
(1) Diabetic ketoacidosis
(2) Hyperammonemia
(3) Bilirubin
ii) Hepatic
iii) Ischemic
iv) Toxic
c) Cerebritis
d) Brain injury and neurosurgery
e) Seizure disorders
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known to increase brain-water content in the absence of
hyponatremia and to impair brain regulatory volume
mechanisms [39–41]. Postoperative patients are at partic-
ularly high risk for developing hyponatremic encephalop-
athy, and this may be explained in part by the high AVP
levels associated with surgery [33]. Hypoxemia is a major
risk factor for developing hyponatremic encephalopathy.
The occurrence of a hypoxic event such as respiratory
insufficiency is a major factor militating against survival
without permanent brain damage in patients with hypona-
tremia [42]. The combination of systemic hypoxemia and
hyponatremia is more deleterious than is either factor
alone because hypoxemia impairs the ability of the brain
to adapt to hyponatremia, leading to a vicious cycle of
worsening hyponatremic encephalopathy [43]. Studies of
hyponatremic animals have revealed that hypoxia impairs
brain-cell-volume regulation, decreases cerebral perfusion,
and increases the probability of developing neuronal
lesions [44].
Underlying CNS disease
Hyponatremia is poorly tolerated in patients with central
nervous system (CNS) disorders [45]. Even a small fall in
SNa can aggravate cerebral edema and increase intracra-
nial pressure (ICP) [46–48]. CNS pathology can lead to
increased ICP from space-occupying brain lesions, hydro-
cephalus, or cerebral edema. Cerebra edema can occur via
two mechanisms: vasogenic and cytotoxic. Vasogenic
edema is the accumulation of fluid in the extracellular
brain parenchyma from a disruption in the blood−brain
barrier, such as is seen with a brain tumor, abscess, or
meningitis. Cytotoxic cerebral edema is the accumulation
of fluid in the intracellular space, which is seen with
hypoxic brain injury, metabolic encephalopathy, and
hyponatremia [49]. These mechanisms are not mutually
exclusive. A patient with a CNS disorder will already be at
risk for increased ICP and have impaired brain-cell-
volume regulation. The additional water movement into
the brain from even mild hyponatremia can be lethal.
It has been demonstrated that in children with a
variety of neurologic diseases that hyponatremia is
associated with prolonged hospital stay and poor neuro-
logic outcome [50]. Similar findings have been reported
in adults with traumatic brain injury [51]. In a study of
children with Lacrosse encephalitis, mild hyponatremia
was strongly associated with neurological deterioration
[46]. SNa of patients with neurological deterioration was
only 2 mmol/L less than in those without (131.9 vs.
1 3 3 . 8m m o l ) ,a n daf a l li nS N ao fo n l y4m m o l / Lr e s u l t e d
in neurological deterioration. In a study in children with
pneumococcal meningitis, the mortality was 100% for
those who presented with SNa <130 mEq/L [52].
Hyponatremia has been reported to lead to progressive
cerebral edema in children with maple-syrup-urine disease
during episodes of acute metabolic intoxication [53]. Mild
hyponatremia, SNa <135 mEq/L, also appears to play a
role in the development of cerebral edema in patients with
diabetic ketoacidosis (DKA). It has been demonstrated on
MRI that patients with DKA have evidence of vasogenic
cerebral edema [54]. The development of worsening
cerebral edema in DKA has been associated with a fall
in serum osmolality during therapy and a slower rise in
serum osmolality compared with controls [55, 56]. No
degree of hyponatremia should be considered safe in a
patient with CNS disease.
& Major risk factors for developing hyponatremic en-
cephalopathy are: (a) age <16 years, (b) hypoxemia,
and (c) CNS disease.
Can hospital-acquired hyponatremia be prevented?
The majority of the morbidity and mortality from
hyponatremic encephalopathy has occurred in hospital-
ized patients receiving hypotonic intravenous fluids, in
particular, postoperative patients. In 2003 [57], we
proposed that 0.9% sodium chloride (NaCl: Na
154 mEq/L) be administered to prevent hospital-acquired
hyponatremia in patients at risk for AVP excess (see
Table 5) and that the routine practice of administration
of hypotonic and near-isotonic intravenous fluids (Na
≤ 130 mEq/L) be abandoned [45, 57, 58]. We recommen-
ded that hypotonic fluids be restricted in their use in
patients with either hypernatremia (Na > 145 mEq/L) or
ongoing urinary or extrarenal free-water losses. This
concept, which challenged the traditional view of fluid
therapy in children, was received with skepticism [59]. The
main criticism of this approach was that 0.9% NaCl could
result in either hypernatremia or fluid overload. Subsequent
Table 5 Primary indications for using 0.9% NaCl in parenteral fluids
for the prevention of hospital-acquired hyponatremia
1. Central nervous system disorders
2. Peri-operative state
a. Ear, nose, and throat (ENT) and orthopedic in particular
3. Volume depletion
4. Hypotension
5. Pulmonary disease
a. Pneumonia and bronchiolitis in particular
6. Hydration for chemotherapy
a. Cytoxan in particular
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hyponatremia and that the administration of 0.9% NaCl
does not result in either hypernatremia or fluid overload.
In 2005, we presented data of >50 reports, from
1992–2004, of death or neurologic dysfunction from
hyponatremic encephalopathy associated with the admin-
istration of hypotonic fluids in children. To the best of
our knowledge, there have been nine additional reports of
hyponatremic encephalopathy related to hypotonic fluids,
with three deaths (Table 6)[ 58, 60–66]. It is estimated
that there are >600 deaths per year from postoperative
hyponatremic encephalopathy in children in the USA and
one death per year in France [34, 65]. In Australia, it is
estimated that about 10% of medical emergencies in the
hospital involve hospital-acquired hyponatremia [67].
Despite the well-documented dangers of using hypotonic
fluids, multiple recent studies in the USA and UK have
revealed that between 80–100% of postoperative children
are still being administered hypotonic fluids (0.18–0.45%
NaCl) [58, 68–70]. In September 2007, the National
Patient Safety Agency in the UK issued a warning about
the use of hypotonic fluids in postoperative children and
children with mild illness and recommended that 0.18%
NaCl be removed from patient care areas [71].
Since our initial recommendations were made in 2003,
there have been at least 11 studies in >1,000 children
confirming our hypothesis that (a) hypotonic fluids,
including Ringer’s Lactate (Na 130 mEq/L), produce
hyponatremia and that (b) isotonic fluids prevent the
development of hyponatremia (Table 7). The most con-
vincing evidence that 0.9% NaCl is effective in preventing
hospital-acquired hyponatremia has come from two recent
prospective randomized studies comparing isotonic to
hypotonic fluids. Yung and Keely conducted a prospective
randomized controlled trial in 50 pediatric patients receiv-
ing either 0.9% NaCl or 0.18% saline at either standard
maintenance or 2/3 maintenance rate [72]. Thirty-six (72%)
were postsurgical. The 0.9% NaCl group had a fall in SNa
of 0.2 mEq/L at 2/3 maintenance and 1.5 mEq/L at full
maintenance, whereas the 0.18% NaCl group had a fall in
SNa of 3 mEq/L at 2/3 maintenance and 4.9 mEq/L at full
maintenance. They concluded that fluid type, not rate, was
associated with a fall in SNa. Montanana et al. similarly
conducted a prospective randomized controlled trial of 122
postoperative pediatric patients admitted to the intensive
care unit who received either an isotonic fluid (Na + K=
155 mEq/L) or hypotonic fluids (Na < 100 mEq/L) [73].
The incidence of hyponatremia (Na < 135) at 24 h was
20.6% in the hypotonic fluid group compared with 5.1% in
the isotonic group. Both studies failed to document any
complications from isotonic fluids, such as hypertension or
hypernatremia.
Based on all the available data, 0.9% NaCl should be the
fluid of choice in maintenance parenteral fluids, especially
in the postoperative setting and in children with CNS or
pulmonary disease. It must be emphasized that 0.9% NaCl
is not appropriate for all clinical circumstances. Normal
saline could result in hypernatremia if given to children
with conditions causing ongoing urinary or extrarenal free-
water losses, such as diabetes insipidus or profuse water
diarrhea. Also, 0.9% NaCl may not always be able to prevent
hyponatremia, in particular, in cases of CNS injury where
there is cerebral salt wasting or Syndrome of Inappropriate
Antidiuretic Hormone Secretion (SIADH) where the urine
osmolality is >500 mOsm/kg. Patients receiving parenteral
fluids should have close monitoring with daily weights,
frequent vitals, strict intake and output measurement, and
daily chemistries, especially during the first 72 h of therapy.
Table 6 Hospital-acquired hyponatremic encephalopathy in children receiving hypotonic fluids (2005–2009)
Authors Age
(years)
Setting Intravenous fluid Sodium
value
(mEq/L)
Symptoms Treatment Outcome
Duke et al. 2005 [61] 19 ALL, dDAVP 0.18% NaCl 138 to 124 Seizures 3% NaCl Survived
2 Medulloblastoma 0.18% NaCl 143 to 119 Seizures & hypoxia 3% NaCl Survived
6 ALL 0.45% NaCl 136 to 125 Seizures & respiratory
depression
3% NaCl Survived
Ashraf and Albert
2006 [64]
0.1 Bronchiolitis 0.22% NaCl 142–107 Lethargy 3% NaCl Survived
Osier et al. 2006 [62] 8 Burkitt’s
lymphoma
0.45% NaCl 138 to 96 Seizures Fluid
restriction
Survived
Agut Fuster et al.
2006 [60]
3.5 Adenoidectomy D5 Water 116 Seizures, comatose 3% NaCl Survived
Donaldson et al.
2007 [63]
5.5 Adrenal
suppression
0.45% NaCl 125 to 123 Seizures, coma, respiratory
arrest,
cardiogenic shock
None Death
Auroy et al. 2008 [65] 4 Dental extraction D5 Water & 0.35%
NaCl
120 Coma, respiratory distress, heart
failure
None Death
Cansick et al. 2009 [126] 11 Renal transplant 0.45 NaCl 140–121 Seizures, cerebral herniation Lorazepam Death
ALL acute lymphoblastic leukemia, dDAVP 1-desamino-8d-arginine vasopressin, NaCl sodium chloride, D5 water 5% dextrose in water
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NaCl is effective in preventing the development of
hospital-acquired hyponatremia.
What is the optimal therapy for treating hyponatremic
encephalopathy?
Hyponatremic encephalopathy is a medical emergency that
requires early recognition and treatment. The definitive
therapy for treating hyponatremic encephalopathy is ad-
ministration of hypertonic saline (3% NaCl, 513 mEq/L).
The majority of morbidity associated with hyponatremic
encephalopathy has resulted from insufficient therapy rather
than overcorrection [9, 74–77]. As can be seen from
Table 6, all recent deaths in children have resulted from
failure to recognize and treat hyponatremic encephalopathy
appropriately. Even in patients who had a good outcome,
many had a significant delay in instituting therapy. This is
consistent with recent data in adults with hyponatremic
encephalopathy that reveal that there is an average delay of
11 h in instituting therapy with 3% NaCl because of either
absence of severe neurological symptoms or failure to
increase the SNa with other therapies [78].
Fluid restriction alone has no role in the management of
symptomatic hyponatremia; 0.9% NaCl is also inappropri-
ate for treating hyponatremic encephalopathy due to non-
hemodynamic states of AVP excess, such as SIADH,
postoperative hyponatremia, and exercise-associated hypo-
natremia, as it is not sufficiently hypertonic to induce the
necessary reduction in cerebral edema central to the
management of this condition [27]. In the presence of
elevated AVP levels, there will be an impaired ability to
excrete free water with the urine osmolality exceeding that
of the plasma. This is a saline-resistant state in which the
urinary electrolyte level can be hypertonic to that of the
plasma. There is a new class of drug called V2-receptor
antagonists (V2RA), or Vaptans, which cannot be recom-
mended for the treatment of hyponatremic encephalopathy
at this time [27]. V2RAs block the binding of AVP to its V2
receptor located in the renal collecting duct [79]. These
drugs are primarily indicated for treating euvolemic
hyponatremia from SIADH and hypervolemic hyponatre-
mia in congestive heart failure. There are no data to suggest
that V2-receptor antagonists will cause either a sufficiently
rapid or sufficiently consistent increase in SNa for it to be
used in the treatment of symptomatic hyponatremia.
Current data indicate that V2-receptor antagonists do not
exert an effect for 1−2h ,w h i c hw o u l dm a k ei ta n
inappropriate agent for symptomatic hyponatremia [79].
The only consistent way of acutely increasing plasma Na is
to administer 3% NaCl, which has a sodium concentration
that exceeds the kidney’s ability to generate free water.
There may be a role for V2-receptor antagonists in
conjunction with 3% NaCl for treating hyponatremic
encephalopathy, but this needs to be further evaluated.
& 3% NaCl is the most effective therapy for treating
hyponatremic encephalopathy.
& V2-receptor antagonists should not be used as the sole
treatment of hyponatremic encephalopathy.
Hypertonic saline (3% NaCl, 513 mEq/L) bolus therapy
for treating hyponatremic encephalopathy
We introduced a new approach to using 3% NaCl for treating
hyponatremic encephalopathy in order to (a) facilitate early
and aggressive therapy and (b) prevent inadvertent over-
correction of hyponatremia (see Table 8). In 2005, we
recommended using a 100-cc bolus of 3% NaCl to treat
exercise-associated hyponatremic encephalopathy [80]. This
approach has since been adopted by the Second International
Exercise-Associated Hyponatremia Consensus Development
Conference [81]. We have since recommended that any
patient with suspected hyponatremic encephalopathy, with
either mild or advanced symptoms, should receive a 2-cc/kg
bolus of 3% NaCl with a maximum of 100 cc [27, 45]. Our
approach has now been recommended by other experts to
treat adults with hyponatremic encephalopathy [82, 83]. A
single bolus would result in at most a 2-mEq/L acute rise in
SNa, which would quickly reduce brain edema. The bolus
could be repeated one or two times if symptoms persist. This
approach can also serve as a diagnostic maneuver, as a
patient who does not show some clinical improvement after
two to three boluses of 3% NaCl most likely is not suffering
from hyponatremic encephalopathy. The advantage of this
approach over a continuous infusion of 3% NaCl is that there
is a controlled and immediate rise in SNa and also little or no
risk of inadvertent overcorrection from a 3% NaCl infusion
Table 8 Treatment of symptomatic hyponatremia
1. 2 cc/kg bolus of 3% NaCl over 10 min. Maximum 100 cc
2. Repeat bolus 1–2 times as needed until symptoms improve. Goal:
5–6 mEql/L increase in serum sodium (SNa) in first 1–2h
3. Recheck SNa following second bolus or Q 2 h
4. Hyponatremic encephalopathy is unlikely if no clinical
improvement following an acute rise in serum sodium of
5–6 mEq/L
5. Stop further therapy with 3% NaCl boluses when patient is either:
a. Symptom free: awake, alert, responding to commands, resolution
of headache and nausea
b. Acute rise in sodium of 10 mEq/L in if first 5 h
6. Correction in first 48 h should:
a. Not exceed 15–20 mEq/L
b. Avoid normo- or hypernatremia
1232 Pediatr Nephrol (2010) 25:1225–1238running too long. No harm could come from using this
approach in a patient with suspected hyponatremic
encephalopathy, even if the patient proves not to have
hyponatremic encephalopathy. It is our opinion that
treatment of suspected symptomatic hyponatremic encepha-
lopathy should begin with a 3% NaCl bolus. This should
precede radiologic investigations because (a) neurologic
deterioration could occur if there is a delay in therapy
and (b) a CT scan cannot always rule out hyponatremic
encephalopathy. This maneuver will stabilize the patient until
further diagnostic studies can be done and serve as a bridge to
instituting other therapies, such as V2-receptor antagonists.
Recommended safe limits for the correction of
hyponatremia vary among experts depending on the
setting of hyponatremia, including from 6 to 8 mEq/L
i n2 4h[ 82], 10 mEq/L in 24 h [84], 15 mEq/24 h [85]o r
20 mEq/L in 48 h [45], as do recommendations for using
hypertonic saline. Our recommendation to use bolus
therapy is a unifying approach that would stay well within
all recommended limits of correction and can be used
safely in any setting, from mildly symptomatic to severe
encephalopathy and in acute or chronic hyponatremia. Our
approach does not rely on formulas or complicated
calculations, and it can be administered safely and quickly
in the emergency department or at the bedside prior to
transfer to a monitored setting.
& A 2 cc/kg bolus of 3% NaCl, maximum 100 cc, should
be administered promptly over 10 min if there are signs
of hyponatremic encephalopathy.
& A 3% NaCl bolus can be repeated one or two times as
needed until symptoms improve.
& The goal of correction should be 5–6 mEql/L in the
first 1−2h .
Who is at risk for developing cerebral demyelination?
A significant barrier to the use of hypertonic saline has
been the perceived risk of developing cerebral demye-
lination from overcorrection of hyponatremia. Cerebral
demyelination is a rare condition that has been reported
in patients with chronic hyponatremia (>48 h) who have
additional risk factors such as liver disease or alcohol-
ism, severe malnutrition, hypoxia, or correction in SNa
of >25 mEq/L in the first 24–48 h of therapy [74]. In
these high-risk patients (see Table 9), it is not clear that
cerebral demyelination is completely preventable, as there
have been multiple reports of cerebral demyelination
occurring with both careful correction or in the absence
of hyponatremia [86–96]. Cerebral demyelination has not
been reported in children with acute hospital-acquired
hyponatremia, nor have neurological complications been
associated with the use of 3% NaCl to treat children with
acute hyponatremic encephalopathy [97–100].
When cerebral demyelination does occur, it can be either
symptomatic or asymptomatic [20]. The classical presenta-
tion typically follows a biphasic pattern, with initial clinical
improvement of hyponatremic encephalopathy associated
with correction of SNa, followed by a neurological
deterioration 2–7 days following correction [42, 101].
Typical neurological features are mutism, dysarthria, spastic
quadriplegia, pseudobulbar palsy, ataxia, and pseudobulbar
palsy with “locked-in stare” [102]. Cerebral demyelination
is best diagnosed by MRI 14 days following correction of
hyponatremia, and the lesions can be both pontine and
extrapontine [103].
& Patients at highest risk for developing cerebral demyelin-
ation have chronic hyponatremia and either (a) liver
disease,(b) malnutrition, (c) hypoxia,or(d) anincreasein
SNa of >25 mEq/l.
& Patients with acute hyponatremia are not at significant
risk for developing cerebral demyelination.
What are the dangers of overcorrection
of hyponatremia?
There are limits to the brain’s ability to maintain cell
volume and cellular integrity when faced with extreme
elevations in osmolality. Animal studies have revealed that
extreme elevations in SNa are injurious to the brain,
producing cellular necrosis, myelinolysis, disruption of the
blood−brain barrier, and increase in cerebral blood flow
[104–110]. For chronically hyponatremic animals, the
threshold for brain injury appears to be an acute elevation
in SNa of 25 mEq/L within 24 h [106, 107, 111, 112].
Table 9 Risk factors for developing cerebral demyelination in
hyponatremic patients
1. Severe chronic hyponatremia: Na ≤115 mEq/L
2. Development of hypernatremia
3. Increase in serum sodium exceeding 25 mmol/L in 48 hours
4. Hypoxemia
5. Severe liver disease
6. Thiazide diuretics
7. Alcoholism
8. Cancer
9. Severe Burns
10. Malnutrition
11. Hypokalemia
12. Diabetes
13. Renal failure
Pediatr Nephrol (2010) 25:1225–1238 1233Chronically hyponatremic rats can be corrected with
hypertonic saline by as much as 20 mEq/L in 1 h without
developing brain pathology [111]. Acutely hyponatremic
and normonatremic animals have a significant mortality
when SNa is increased by >25 mEq/L but a much lower
incidence of brain injury when compared with chronically
hyponatremic animals [104–106, 113, 114]. Clinical obser-
vations in chronically hyponatremic humans also suggest
that increases in SNa of >25 mEq/L in 48 h can result in
neurologic impairment [9, 74]. Based on these animal
studies and clinical observations, increases in SNa of a
magnitude >25 mEq/L in a 48-h period should be avoided.
& Acute elevations in SNa exceeding 25 mEq/L in 48 h
can produce brain injury.
Can inadvertent overcorrection of hyponatremia
be prevented?
Preventing an extreme rise in SNa (>25 mEq/L in 48 h) can
be difficult, particularly in the severely hyponatremic
patient (SNa ≤ 115 mEq/L). The overall rate of correction
of hyponatremia is primarily a determinant of the renal
response to fluid therapy, more so than the composition of
fluids administered. Under most circumstances, hyponatre-
mia develops due to a state of high AVP production. Once
the stimulus for AVP production abates, there will be brisk
urinary excretion of free water and hyponatremia will
correct rapidly. The main conditions in which correction by
fluid therapy will induce a brisk free-water diuresis are (a)
thiazide-induced hyponatremia, (b) water intoxication, (c)
gastroenteritis, (d) adrenal insufficiency following replace-
ment therapy, and (e) 1-desamino-8d-arginine vasopressin
(dDAVP)-induced hyponatremia following dDAVP with-
drawal. Even in patients who are not typically at high risk
for overcorrection, such as those with SIADH and
postoperative hyponatremia, when the stimuli for AVP
production abates, a free-water diuresis will ensue. It is
important to recognize that equations for predicting the
correction of hyponatremia will not apply in these patients,
as most of these equations are closed-system equations that
due not take into account the renal response to fluid therapy
[19, 78]. In general, if the SNa is >115 mEq/L, then even if
there is a brisk free-water diuresis, the absolute rise in SNa
will not likely exceed 25 mEq/L, and the risk of brain
injury is small.
We recommend that the following measures be taken to
prevent overcorrection of hyponatremia: (1) Patients with
an SNa <115 mEq/L should be monitored to see whether a
water diuresis ensues, as evidenced by an increase in SNa
of >1 mEq/L per hour accompanied by a urine flow rate of
>1 ml/kg per hour. In general, a urine tonicity (urine
Na + K) <80 mEq/L or urine osmolality less than that of the
plasma is consistent with a significant free-water diuresis
during the correction phase of hyponatremia. (2) Hydration
with either 3% NaCl or 0.9% NaCl should be limited to the
minimal amount necessary to correct the SNa to a safe level
or correct volume depletion. (3) Sodium-containing intra-
venous fluid should be restricted once a free-water diuresis
commences, and oral intake should be encouraged. (4)
Parenteral fluids, when needed, should be hypotonic, Na
concentration <80 mEq/L, if there is a free-water diuresis.
On the rare occasion that a pediatric patient with severe
hyponatremia fails these above measures, the administra-
tion of dDAVP could be considered. DDAVP administra-
tion was first suggested to prevent the overcorrection of
hyponatremia in 1993 [115] and has subsequently been
used successfully in adult patients [116, 117]. DDAVP has
also been used successfully to therapeutically re-lower the
SNa in an adult patient with overcorrection of chronic
hyponatremia. dDAVP should be used with caution and in
consultation with someone familiar with this therapy, as it
can result in inadvertent hyponatremia. If used, hypotonic
fluid administration should be avoided following the
administration of dDAVP, and isotonic saline should be
administered at a restricted rate when needed. An inadver-
tent lowering of the SNa following dDAVP administration
can be corrected with a bolus of 3% NaCl.
Management of dDAVP-induced hyponatremia
Hyponatremia caused by dDAVP is particularly difficult to
manage. Hyponatremic encephalopathy from dDAVP-
induced hyponatremia has been reported in children taking
this medication for the treatment of enuresis, central
diabetes insipidus (CDI), and as part of perioperative
management of Von Willebrand’s disease [118, 119]. A
common and dangerous way to manage dDAVP-induced
hyponatremia is by stopping dDAVP and administering
0.9% NaCl. This can result in an overcorrection of
hyponatremia, as withdrawal of dDAVP will result in a
free-water diuresis, and in combination with 0.9% NaCl or
3% NaCl, hypernatremia could develop, especially in the
case of CDI, where there will not be endogenous AVP
production in response to hyperosmolality [120]. This is
particularly likely to occur when the SNa is <115 mEq/L.
We have previously reported on cases of brain injury from
overcorrection of hyponatremia following dDAVP with-
drawal [120]. The safer approach is to continue the dDAVP
to allow controlled correction in SNa. Then, 3% NaCl
boluses can be administered as needed to correct the SNa.
Fluid restriction should then be instituted, with isotonic
fluids used in parenteral fluids if needed. Once the SNa has
been corrected to mildly hyponatremic values, dDAVP
could be discontinued.
1234 Pediatr Nephrol (2010) 25:1225–1238& dDAVP should not be discontinued in the management
of dDAVP-induced hyponatremia.
Questions
(Answers appear following the reference list)
1. Whatis themainriskfactorfordevelopinghyponatremia?
a. AVP excess
b. Intravenous fluid therapy
c. Prematurity
d. Prolonged hospitalization
e. Mechanical ventilation
2. Which of the following is NOTa feature of hyponatremic
encephalopathy?
a. Headache
b. Noncardiogenic pulmonary edema
c. Hyperpyrexia
d. Seizures
e. Orthopedic injuries
3. Why are children at increased risk for developing
hyponatremic encephalopathy?
a. Increased expression of aquaporin 4
b. Increased sensitivity of AVP
c. Increased basal metabolic rate
d. Increased brain- to skull-size ratio
e. Increased brain idiogenic osmole production
4. What is the most effective therapy of hyponatremic
encephalopathy?
a. Vasopressin 2 antagonists
b. Mannitol
c. 0.9% NaCl plus Lasix
d. Craniotomy
e. 3% NaCl
5. Which of the following is NOT a risk factor for
developing cerebral demyelination?
a. Liver disease
b. Acute hyponatremic encephalopathy
c. Hypoxia
d. Correction in SNa of >25 mEq/L in 48 h
e. Thiazide diuretics
Note added in proof
Following the submission of this manuscript, Neville et
al. [134] reported on a prospective randomized trial of 124
postoperative children who received either 0.9% NaCl or
0.45% NaCl at either 100% or 50% of standard mainte-
nance. The incidence of hyponatremia (Na < 135) within
the first 24 hours of surgery was 30% in the 0.45% NaCl
group compared to 10% in the 0.9% NaCl (p=0.02), with
15% of patients in the 0.45% NaCl group having a fall in
SNa of Q5 mEq/L compared to none in the 0.9% NaCl.
Fluid restriction at 50% maintenance did not decrease the
incidence of hyponatremia, but resulted in a 23% incidence
of dehydration. Administration of 0.9% NaCl did not result
in clinically significant hypernatremia.
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